

HOTLINE: Effective November 14, 2022

| New Test | 3005860 | Trazodone, Serum or Plasma | TRAZO SP | |
|-----------------------|--|---|---|--|
| Methodology: | Liquid Chromatography-Tandem Mass Spectrometry | | | |
| Performed: | Wed | | | |
| Reported: | 1-8 days | | | |
| - Specimen Require | ed: Patient Prep: T | iming of specimen collection: Pre-dose (trough) draw - At steady state co | ncentration. | |
| - Specimen Require | ed: Patient Prep: T | iming of specimen collection: Pre-dose (trough) draw - At steady state co | ncentration. | |
| - Specimen Require | Collect: Plain r | iming of specimen collection: Pre-dose (trough) draw - At steady state coned. Also acceptable: Lavender (K_2 or K_3 EDTA) or pink (K_2 EDTA). | | |
| - Specimen Require | Collect: Plain r Specimen Prep | ed. Also acceptable: Lavender (K_2 or K_3 EDTA) or pink (K_2 EDTA). aration: Separate serum or plasma from cells within 2 hours of collection. | | |
| - Specimen Require | <u>Collect:</u> Plain r <u>Specimen Prep</u> Standard Trans | ed. Also acceptable: Lavender (K_2 or K_3 EDTA) or pink (K_2 EDTA). aration: Separate serum or plasma from cells within 2 hours of collection. port Tube. (Min: 0.5 mL) | | |
| - Specimen Require | <u>Collect:</u> Plain r <u>Specimen Prep</u> Standard Trans | ed. Also acceptable: Lavender (K_2 or K_3 EDTA) or pink (K_2 EDTA). aration: Separate serum or plasma from cells within 2 hours of collection. | | |
| - Specimen Require | <u>Collect:</u> Plain r <u>Specimen Prep</u> Standard Trans <u>Storage/Transp</u> | ed. Also acceptable: Lavender (K_2 or K_3 EDTA) or pink (K_2 EDTA). aration: Separate serum or plasma from cells within 2 hours of collection. port Tube. (Min: 0.5 mL) | Transfer 1 mL serum or plasma to an ARU | |

Reference Interval:

| Therapeutic Range: | 800-1600 ng/mL |
|--------------------|----------------------|
| Toxic: | Not well established |

Interpretive Data:

Trazodone is a selective serotonin reuptake inhibitor antidepressant drug indicated for the treatment of major depressive disorder. The pharmacokinetics of trazodone is influenced by drug-drug interactions that induce or inhibit CYP3A4 metabolism. Adverse effects may include sedation, fatigue, headache, blurred vision, nausea, and cardiac arrhythmia. The risk of serotonin syndrome is increased with concomitant use of other serotonergic drugs. Concomitant use of trazodone with anticoagulants and nonsteroidal anti-inflammatory drugs may increase the risk of bleeding.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

CPT Code(s): 80338 (Alt code: G0480)

New York DOH Approved.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.